ICON and the University of Cambridge Collaborate to Deliver Educational Programme on Pricing & Market Access Strategy

Dublin, Ireland – ICON plc, (NASDAQ: ICLR) a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that its Pricing and Market Access practice is collaborating with the Institute of Biotechnology at the University of Cambridge to deliver a 5-day education programme on pricing and market access strategies for biopharmaceutical products. 

Led by key opinion leaders from the pricing and market access industry and academia, the course takes place from 22-26 September 2014 and will teach the foundations and best practices in value-based pricing through specialised lectures and industry case studies. Attendees will learn how the pricing strategy integrates with the overall product strategy and how health economics and outcomes research can support and complement the deployment of a pricing strategy. The course will also familiarise attendees with specific tools to design a value strategy. These will include the initial value strategy definition, the communication of value to payers, and finally, to capture the value with the appropriate price level capable of supporting the desired level of access and return on investment.

Commenting on the collaboration, Ted Sweeney, ICON's Executive Vice President, Commercialisation & Outcomes, said: "Pricing and market access strategies that protect the long term value of a product are becoming increasingly important in an environment where payers are targeting pharmaceuticals to bring healthcare budgets under control. We are proud of our long association with the University of Cambridge and look forward to working together to share our extensive experience to help biopharmaceutical professionals define a clear, quantified product value proposition."

Commenting on the programme, Professor Chris Lowe, Director of the Institute of Biotechnology said: "The success of our professional practice postgraduate business programmes is testament to the growing interest in the biopharmaceutical business arena. We benefit greatly from leveraging the wealth of knowledge from ICON's Pricing and Market Access practice."

About the Biopharma Professional Practice Programme
The course will be held at the Institute of Biotechnology, Tennis Court Road, Cambridge, CB2 1QT. The Institute is part of the Department of Chemical Engineering and Biotechnology and is located in central Cambridge.
Course Fees: 

  • Complete programme: £5000 (Early booking rate: £3500) 
  • Individual module(s): £1500 each (Early booking rate: £1000) 
  • Early booking deadline: 31 July 2014
  • Multiple delegate discounts available; please contact us for further details 

To register, please email: [email protected] 

ICON's Pricing and Market Access practice is dedicated to generating valuable recommendations for pricing products that drive strategies to bring products to market effectively. By delivering robust value strategies, designing efficient pricing and market access infrastructures and processes, ICON's unique strategic approach combines experiential assessment with rigorous quantitative analysis and research. Utilising a direct network of 1,000+ payer stakeholders, and access to a multitude of market specialists, ICON delivers pricing and market access services throughout the product life cycle.

About ICON plc 
ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON currently has approximately 11,100 employees, operating in 39 countries. Further information is available at www.iconplc.com.

About University of Cambridge Department of Chemical Engineering and Biotechnology
University of Cambridge is consistently ranked amongst the world's top Universities, and its Department of Chemical Engineering and Biotechnology has an outstanding reputation for interdisciplinary scientific research and innovation; from development and commercialisation of innovative healthcare technologies to diagnose, treat and combat disease to finding new ways to create sustainable energies and conserve the environment. In offering the Biopharma professional practice course, the department recognises the vital relationship between knowledge transfer and economic growth and leads the way in which industry leaders, scientists and entrepreneurs work together to find innovative solutions to a range of commercial challenges. 

ICON Media Contact
Rebecca Power
Weber Shandwick
T 44 (0) 207 067 0866 
E [email protected]

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

WCG is continuing its buyout run after acquiring clinical trial solutions firm Trifecta Clinical.

London-based uMed has raised nearly $4.8 million from U.K. and U.S. VCs to help healthcare providers participate in more clinical studies.

Amgen has teamed up with cloud-based trial solutions firm Reify Health to help boost patients into its drug studies.